Met Life Investment Management, LLC C4 Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

$18 Billion
Q4 2024

A detailed history of Met Life Investment Management, LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 28,854 shares of CCCC stock, worth $78,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,854

Previous 35,455 18.62%

Holding current value

$78,194

Previous $202,000 49.01%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$3.6 - $7.0 $23,763 - $46,207	-6,601 Reduced 18.62%	28,854 $103,000
Q3 2024 Nov 13, 2024	BUY	$4.43 - $7.38 $88,502 - $147,437	19,978 Added 129.08%	35,455 $202,000
Q2 2024 Aug 13, 2024	BUY	$4.05 - $8.1 $62,681 - $125,363	15,477 New	15,477 $71,000
Q1 2023 May 09, 2024	BUY	$3.1 - $9.02 $85,172 - $247,824	27,475 New	27,475 $86.3 Million
Q3 2022 May 10, 2024	BUY	$8.03 - $12.77 $51,094 - $81,255	6,363 Added 30.14%	27,475 $240,000
Q3 2022 Mar 22, 2023	BUY	$8.03 - $12.77 $51,094 - $81,255	6,363 Added 30.14%	27,475 $240,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $51,094 - $81,255	6,363 Added 30.14%	27,475 $241,000
Q2 2022 Jun 20, 2023	SELL	$5.06 - $26.46 $32,196 - $168,364	-6,363 Reduced 23.16%	21,112 $159,000
Q1 2022 May 10, 2024	BUY	$19.99 - $33.23 $422,028 - $701,551	21,112 New	21,112 $512,000
Q1 2022 Jun 20, 2023	SELL	$19.99 - $33.23 $127,196 - $211,442	-6,363 Reduced 23.16%	21,112 $512,000
Q1 2022 Mar 22, 2023	BUY	$19.99 - $33.23 $155,762 - $258,928	7,792 Added 58.5%	21,112 $512,000
Q1 2022 May 12, 2022	BUY	$19.99 - $33.23 $155,762 - $258,928	7,792 Added 58.5%	21,112 $512,000
Q4 2021 Jun 21, 2023	SELL	$29.39 - $46.86 $416,015 - $663,303	-14,155 Reduced 51.52%	13,320 $428,000
Q3 2021 Jun 21, 2023	SELL	$35.91 - $50.5 $508,306 - $714,827	-14,155 Reduced 51.52%	13,320 $595,000
Q2 2021 May 17, 2024	BUY	$30.39 - $42.18 $242,269 - $336,258	7,972 Added 149.07%	13,320 $504,000
Q2 2021 Jun 21, 2023	SELL	$30.39 - $42.18 $430,170 - $597,057	-14,155 Reduced 51.52%	13,320 $504,000
Q2 2021 Mar 22, 2023	BUY	$30.39 - $42.18 $242,269 - $336,258	7,972 Added 149.07%	13,320 $504,000
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $242,269 - $336,258	7,972 Added 149.07%	13,320 $504,000
Q1 2021 May 17, 2024	BUY	$31.96 - $46.5 $170,922 - $248,682	5,348 New	5,348 $197,000
Q1 2021 Jun 26, 2023	SELL	$31.96 - $46.5 $707,178 - $1.03 Million	-22,127 Reduced 80.54%	5,348 $198 Million
Q4 2020 May 24, 2024	BUY	$22.8 - $37.05 $121,934 - $198,143	5,348 New	5,348 $177,000
Q4 2020 Jun 22, 2023	SELL	$22.8 - $37.05 $504,495 - $819,805	-22,127 Reduced 80.54%	5,348 $177,000
Q4 2020 Mar 22, 2023	SELL	$22.8 - $37.05 $504,495 - $819,805	-22,127 Reduced 80.54%	5,348 $177,000
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $121,934 - $198,143	5,348 New	5,348 $177,000

Others Institutions Holding CCCC

# of Institutions

126

Shares Held

63M

Call Options Held

651K

Put Options Held

115K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $133M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC C4 Therapeutics, Inc. Transaction History